O'Connor Daniel J.
SEC-identified person · CIK 1376847 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Diamedica Therapeutics Inc. DMAX | Director | filed 2025–2026 |
| Ambrx Biopharma, Inc. AMAM | Director · President and CEO | filed 2023–2024 |
| Seelos Therapeutics, INC. SEEL | Director | filed 2019–2024 |
| Ambrx Biopharma Inc. AMAM | Director · President and CEO | filed 2023–2023 |
| Zyversa Therapeutics, Inc. ZVSA | Director · Chief Executive Officer | filed 2021–2022 |
| Oncosec Medical Inc ONCS.OB | Director · Chief Executive Officer | filed 2017–2021 |
| Ayala Pharmaceuticals, Inc. ADXS | Director · SVP, Legal & Business Dev Off | filed 2013–2017 |
| Imclone Systems INC/DE IMCL | VP, INTERIM GEN. COUNSEL, SEC. | filed 2006–2007 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.